Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Leap Therapeutics, Inc. (LPTX) had Consolidated Net Income/Loss of $-15.44M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-15.44M |
|
-- |
|
-- |
|
$15.92M |
|
$-15.92M |
|
$0.48M |
|
$-15.44M |
|
$-15.44M |
|
$-15.44M |
|
$-15.44M |
|
|
Consolidated Net Income/Loss |
$-15.44M |
$-15.44M |
|
$-15.92M |
|
$-15.92M |
|
41.27M |
|
41.27M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$33.87M |
|
-- |
|
$1.01M |
|
$34.88M |
|
$14.04M |
|
-- |
|
-- |
|
$14.04M |
|
$20.84M |
|
$20.84M |
|
$20.84M |
|
41.44M |
|
| Cash Flow Statement Financials | |
$-14.48M |
|
-- |
|
$-0.06M |
|
$47.25M |
|
$32.71M |
|
$-14.54M |
|
$1.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.41 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-74.06% |
|
-74.06% |
|
-44.25% |
|
-74.06% |
|
$0.50 |
|
$-0.35 |
|
$-0.35 |
|